Manufacturing’s cutting edge — custom organisms
- March 23, 2015
Local synbio companies like Ginkgo and Cambridge-based Gen9 , which supplies much of the DNA that Ginkgo uses, are still small. But the industry “is going to grow quickly, especially in Boston,” Harvard Medical School professor Pamela Silver says. A nonprofit in Cambridge called iGEM runs an international competition that teaches college and high school students about synbio, “training the workforce of the future,” vice president Meagan Lizarazo said.
Joi Ito: Want to innovate? Become a “now-ist”
- November 4, 2014
In this lab, we will have the world's capacity of gene printing within a year, 200 million base pairs a year. This is kind of like when we went from transistor radios wrapped by hand to the Pentium. This is going to become the Pentium of bioengineering, pushing bioengineering into the hands of dorm rooms and startup companies.
5 technologies that are shaping the future of design
- March 11, 2014
Design isn’t just a tool for the material and digital worlds, it can also be important for the biological world....two startups working on biology-based printing including Gen9, and Organovo.
How Designer Microbes and the Organism Industry Will Reshape Our World
- March 2, 2014
What would a computer be without transistors? Well, not much. A similar question can be asked of next-generation industrial biotech platforms enabled by synthetic biology...
Accelerating Gene Synthesis Gen9 Automates DNA Construct Production via the Use of Next-Generation Techniques
- February 2, 2014
Gen9 believes it has found its niche in the synthetic nucleotide market by focusing on the automated production of DNA constructs. “We’re democratizing synthetic biology, making it more accessible,” says Kevin Munnelly, president and CEO. “Our scalable technology allows us to make genes, pathways, and genomes at a much larger scale.”
Could a Stockroom be the Next Great Scientific Revolution?
- June 12, 2013
Are gene sequences the Legos of the future?
Gen9, a Cambridge gene synthesis firm, gets $21m investment from Agilent Technologies
- April 24, 2013
Agilent Technologies Inc. has made a $21 million investment in Gen9 Inc., a Cambridge company specializing in gene synthesis.